Sadly docetaxel did not improve OS in the M0 population in STAMPEDE. Contrast to the abiraterone data in same group so clearly different biology at play here

You can mathematically and logically prove that measuring lipids more often than once in a lifetime is a waste of time (for non-FH people). Check out my new video. If I'm wrong, happy to send a bottle of wine to the first person who proves I'm wrong 👍🍷youtu.be/Q1MhrVB2tFE

Must read

So we still need molecular selection for PARPi EU Medicines Agency

I would not offer ARI plus PARPi in unselected patients. Toxicity goes up and efficacy goes down outside a trial. Instead I would aim to use all therapies proven to prolong OS in sequence and look for biologically relevant trials.

Wondering what to read over the weekend? We have a hot-off-the-press paper on whether adjuvant pembro is really needed for renal cell cancer. This paper will also discuss not what to think but how to think about adjuvant therapies in general. ascopubs.org/doi/full/10.12…

New data from ICECaP “Our aggregate screening method for surrogate end points in advanced prostate cancer showed that commonly used clinical end points are not clear valid surrogate end points for OS.” evidence.nejm.org/doi/full/10.10…

A cheap and simple intervention that prolongs DFS and OS. Amazing work from Dr Badwe, Nita Nair Tata Memorial Hospital ACTREC-TMC OncoAlert #breastcancer #oncology #bccww #BCSM ascopubs.org/doi/abs/10.120…

Wow. This is exactly why there should be mandatory crossover when the drug is already SOC in later lines. We are over treating by giving cdk4/6 to everyone 1L. This trial should make news! Bringing common sense back to cancer care! Common Sense Oncology #ASCO23

Highly relevant practice changing trial! #ASCO23

So our inaugural CSO paper- our manifesto- is just out with invitation to all stakeholders to join our movement. Common Sense Oncology is all about outcomes that matter to our patients, and how to ensure that our goals are aligned towards improving these outcomes. thelancet.com/journals/lanon… 1/

Yes, nice piece by steven joniau Wouter Everaerts and Thomas Van De Broeck. Already at the ASCO 2015 presentation Ian Tannock was skeptical of the positive RTOG 0521 results.

Hot off the press in Journal of Clinical Oncology from the Common Sense Oncology team. We argue that PFS should not be used as the primary endpoint for registration trials of anti cancer drugs. ascopubs.org/doi/full/10.12… Elizabeth Eisenhauer Ian Tannock #ChrisBooth

Open for inclusion: Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers (THUNDER): A Two-part Phase 2/ 3 Trial.

Immensely grateful for having received the #ESTRO24 award on behalf of the STORM team honoring the legacy of Prof. Donal Hollywood. Please find the main findings below. Supported by @komop_tgkanker and Movember USA

Important #alliance trial! oxybutinin 5mg bid provided strong benefits in reducing hot flashes for prostate cancer patients on ADT+/-abi. No safety concern.

ARANOTE: Giving ADT monotherapie to de novo high volume patients ....REALLY??? What ethics board approved that? After STAMPEDE and CHAARTED.... OncoAlert

Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer is the 1st perioperative immune therapy study to show an OS in bladder cancer. Published in @nejm gbr01.safelinks.protection.outlook.com/?url=https%3A%…

🚨Highlights from #ESMO2024! Dr Tom Van den Mooter & Dr Michiel Strijbos share key findings on Ra-223, enzalutamide, and new AR ligands in mCRPC. Watch now! 👀medimix.be/onco/esmo-barc… #MediMix #Oncology #GUCancer #ProstateCancer #CancerResearch #ClinicalTrials